6533b7dcfe1ef96bd1271f5d
RESEARCH PRODUCT
Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature.
Ombretta AnnibaliSergio SiragusaMariasanta NapolitanoGiuseppe Avvisatisubject
medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentvenous thromboembolismLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyVte prophylaxis03 medical and health sciences0302 clinical medicineAntithromboticmedicineAnimalsHumanscardiovascular diseasesIntensive care medicineChemotherapybusiness.industryIncidence (epidemiology)IncidenceCancerAnticoagulantsHematologyVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseaseThrombocytopeniaSevere thrombocytopeniaOncology030220 oncology & carcinogenesisHematologic NeoplasmsbusinessVenous thromboembolismdescription
Venous Thromboembolism (VTE) frequently complicates the course of hematologic malignancies (HM) and its incidence is similar to that observed in high-risk solid tumors. Despite that, pharmacologic prophylaxis and treatment of VTE in patients with HM is challenging, mainly because a severe thrombocytopenia frequently complicates the course of treatments or may be present since diagnosis, thus increasing the risk of bleeding. Therefore, in this setting, safe and effective methods of VTE prophylaxis and treatment have not been well defined and hematologists generally refer to guidelines produced for cancer patients that give indications on anticoagulation in patients with thrombocytopenia. In this review, besides to summarize the incidence and the available data on prophylaxis and treatment of VTE in HM, we give some advices on how to use antithrombotic drugs in patients with HM according to platelets count.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-04-01 | Critical reviews in oncology/hematology |